For research use only. Not for therapeutic Use.
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease[1].
Telitacicept (15 and 7.5mpk, i.p.) improves mouse experimental autoimmune encephalomyelitis (EAE) clinical symptoms in MOG35-55 induced EAE model mice[2].
| Catalog Number | I042120 |
| CAS Number | 2136630-26-5 |
| Purity | ≥95% |
| Reference | [1]. Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021 Apr 1;159:105704. [2]. Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences. March 31, 2022. |
